 In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon® is working well enough to support a regulatory filing in 2014.This is the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant 

In April 2014, Agenus inked a deal with Merck potentially worth $100 million.